Apellis Pharma
Apellis Pharmaceuticals, often referred to simply as Apellis, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, the company has made significant strides in the field of complement biology, focusing on innovative therapies for rare diseases and serious conditions. With a strong operational presence in North America and Europe, Apellis is dedicated to transforming the treatment landscape for patients with unmet medical needs. The company’s flagship product, pegcetacoplan, is a groundbreaking therapy designed to address conditions such as paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration. Apellis stands out in the industry for its commitment to advancing complement inhibition, positioning itself as a pioneer in this specialised area. With a robust pipeline and a focus on patient-centric solutions, Apellis Pharmaceuticals continues to solidify its reputation as a key player in the biopharmaceutical sector.
DitchCarbon Score
How does Apellis Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apellis Pharma's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apellis Pharma's reported carbon emissions
Apellis Pharma, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As a result, Apellis Pharma's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent or related organization. The absence of reported emissions and reduction strategies highlights a potential area for improvement in their environmental sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apellis Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
